Suppliers and packagers for generic pharmaceutical drug: EZETIMIBE; SIMVASTATIN

EZETIMIBE; SIMVASTATIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alkem Labs Ltd	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	209222	ANDA	A-S Medication Solutions	50090-4772-0	90 TABLET in 1 BOTTLE (50090-4772-0)	2017-12-24
Alkem Labs Ltd	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	209222	ANDA	Ascend Laboratories, LLC	67877-507-01	1000 TABLET in 1 BOTTLE (67877-507-01)	2017-12-24
Alkem Labs Ltd	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	209222	ANDA	Ascend Laboratories, LLC	67877-507-30	30 TABLET in 1 BOTTLE (67877-507-30)	2017-12-24

Ezetimibe and Simvastatin: Key Supplier Landscape Analysis

Last updated: February 19, 2026

This report analyzes the primary suppliers of Ezetimibe and Simvastatin active pharmaceutical ingredients (APIs) and intermediates. It examines the geographic distribution of these suppliers, their reported manufacturing capacities, and regulatory compliance profiles. The objective is to provide critical intelligence for pharmaceutical companies navigating supply chain risks and strategic sourcing for these widely prescribed medications.

Who are the leading global manufacturers of Ezetimibe API?

The global Ezetimibe API manufacturing landscape is concentrated among a limited number of producers, with significant operations based in India and China. These suppliers cater to the demand for both branded and generic formulations of Ezetimibe, a cholesterol absorption inhibitor.

• Key Ezetimibe API Suppliers:

  • Zydus Lifesciences (formerly Cadila Healthcare): Headquartered in India, Zydus Lifesciences is a prominent manufacturer with substantial Ezetimibe production capacity. The company holds multiple US FDA and EDQM certifications for its API facilities. Recent regulatory filings indicate ongoing investments in expanding its API manufacturing footprint in India.
  • Divi's Laboratories: Another major Indian API producer, Divi's Laboratories, is a significant supplier of Ezetimibe. Their manufacturing sites in India are regularly inspected by international regulatory bodies, including the US FDA, EMA, and PMDA. Divi's has reported consistent API output for Ezetimibe, meeting stringent quality standards.
  • Laurus Labs: Based in India, Laurus Labs has established itself as a key player in the Ezetimibe API market. The company's manufacturing facilities are compliant with cGMP regulations and have undergone audits by major pharmaceutical companies and regulatory agencies. Laurus Labs has publicly stated its focus on expanding its portfolio of complex APIs, including Ezetimibe.
  • Ascend Therapeutics: While Ascend Therapeutics primarily focuses on finished dosage forms, its supply chain relies on API manufacturers. Ascend sources Ezetimibe API from approved vendors primarily located in India and China, with a strong emphasis on supplier audits and regulatory compliance.
  • Various Chinese Manufacturers: Several Chinese pharmaceutical chemical companies produce Ezetimibe API. These include entities such as Zhejiang NHU Co., Ltd. and Jiangsu Hengrui Medicine Co., Ltd. These companies often compete on price and scale, supplying to both domestic and international markets. Regulatory compliance varies, with some facilities holding GMP certifications from recognized authorities.

• Geographic Distribution of Ezetimibe API Manufacturing:

  • India: Dominates the global supply of Ezetimibe API, accounting for approximately 60-70% of the market share. This dominance is driven by established manufacturing infrastructure, skilled workforce, and cost competitiveness.
  • China: Represents the second-largest manufacturing hub for Ezetimibe API, contributing around 20-30%. Chinese manufacturers are increasingly focusing on improving quality standards to meet international regulatory requirements.
  • Europe and North America: Limited API manufacturing of Ezetimibe occurs in these regions, primarily for niche or specialized applications, or by companies focusing on backward integration for their proprietary formulations.

• Capacity and Scale: Leading Ezetimibe API manufacturers typically operate multi-tonnage annual production capacities. Specific figures are often proprietary, but annual capacities for major players are estimated to range from 100 to 500 metric tons per year for key molecules like Ezetimibe.

What are the primary suppliers for Simvastatin API?

Simvastatin, a widely used statin medication, is manufactured by a broader base of API producers compared to Ezetimibe. The supply chain for Simvastatin is well-established, with a strong presence of manufacturers in India and China, alongside some European producers.

• Key Simvastatin API Suppliers:

  • Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company, Dr. Reddy's is a significant producer of Simvastatin API. Their manufacturing sites adhere to international cGMP standards and are approved by regulatory agencies worldwide, including the US FDA and EMA.
  • Sun Pharmaceutical Industries: The largest pharmaceutical company in India, Sun Pharma, is a key supplier of Simvastatin API. Sun Pharma operates numerous state-of-the-art manufacturing facilities that are compliant with global regulatory requirements.
  • Aarti Industries: Based in India, Aarti Industries is a specialty chemical company with a strong pharmaceutical intermediates and API division. They manufacture Simvastatin API and its key intermediates, leveraging their expertise in complex chemical synthesis. Aarti Industries' facilities are subject to rigorous quality control and regulatory audits.
  • Teva Pharmaceutical Industries: While known for its generic finished dosage forms, Teva also has API manufacturing capabilities. Teva produces Simvastatin API for internal use and for sale to other pharmaceutical companies. Their global manufacturing network includes sites in Europe and North America that meet stringent regulatory standards.
  • Mylan (now part of Viatris): Mylan, prior to its merger with Pfizer's Upjohn to form Viatris, was a significant global player in generic APIs. Viatris continues to produce Simvastatin API at its manufacturing facilities, adhering to cGMP guidelines and undergoing regular regulatory inspections.
  • Chinese Manufacturers: Companies such as Jiangsu Changfeng Pharmaceutical Co., Ltd., and Anhui Dechang Pharmaceutical Co., Ltd., are notable Chinese producers of Simvastatin API. They contribute to the global supply, often offering competitive pricing.

• Geographic Distribution of Simvastatin API Manufacturing:

  • India: Remains the largest global supplier of Simvastatin API, estimated to control over 50% of the market share. India's cost-effective manufacturing environment and strong regulatory adherence make it a preferred sourcing location.
  • China: Holds a substantial share in Simvastatin API production, estimated at 30-40%. Chinese manufacturers have expanded their capacity and improved quality management systems.
  • Europe: Several European countries, including Italy and Germany, have API manufacturers that produce Simvastatin. These suppliers often focus on higher-value intermediates or cater to specific European market needs.
  • North America: Limited Simvastatin API manufacturing exists in North America, with a greater focus on finished product formulation and distribution.

• Capacity and Scale: Simvastatin API production is characterized by large-scale manufacturing. Major producers typically have annual capacities exceeding 500 metric tons, with some larger entities capable of producing over 1,000 metric tons annually.

What are the regulatory compliance requirements for these suppliers?

Suppliers of Ezetimibe and Simvastatin API must adhere to a comprehensive set of international regulatory standards to ensure product quality, safety, and efficacy. Non-compliance can lead to supply disruptions, import bans, and significant financial penalties.

• Key Regulatory Bodies and Standards:

  • U.S. Food and Drug Administration (US FDA): Mandates compliance with Current Good Manufacturing Practices (cGMP) for all APIs intended for the U.S. market. FDA inspections evaluate facility design, manufacturing processes, quality control, and documentation.
  • European Medicines Agency (EMA): Enforces EU GMP guidelines. APIs imported into the EU must be accompanied by a Written Confirmation from the exporting country's competent authority, confirming compliance with EU GMP standards.
  • Pharmaceuticals and Medical Devices Agency (PMDA) of Japan: Regulates API manufacturing for the Japanese market, requiring adherence to Japanese GMP standards.
  • World Health Organization (WHO): Provides GMP guidelines that are widely adopted globally, particularly in countries without their own robust regulatory frameworks.
  • EDQM (European Directorate for the Quality of Medicines & HealthCare): Issues Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). A CEP demonstrates that an API complies with the relevant European Pharmacopoeia monograph, facilitating the regulatory approval process in Europe.
  • Other National Regulatory Authorities: Countries like Canada (Health Canada), Australia (TGA), and Brazil (ANVISA) have their own GMP requirements and inspection processes.

• Common Compliance Metrics and Audits:

  • Drug Master Files (DMFs): API manufacturers submit DMFs to regulatory authorities (e.g., FDA, Health Canada). These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the API. Pharmaceutical companies reference these DMFs in their drug product applications.
  • Certificates of Analysis (CoAs): Each batch of API must be accompanied by a CoA, which details the results of quality control tests performed on that specific batch, confirming it meets predefined specifications.
  • Routine Inspections: Regulatory agencies conduct periodic inspections of API manufacturing facilities. Successful inspections are critical for maintaining approval to supply APIs to regulated markets.
  • Customer Audits: Pharmaceutical companies that purchase APIs conduct their own audits of supplier facilities to assess compliance, quality systems, and risk management practices.

• Impact of Non-Compliance:

  • Warning Letters and Import Alerts: Issued by the US FDA for significant cGMP violations. Import alerts can halt the entry of APIs into the U.S.
  • Recalls: Product recalls can be initiated if an API is found to be substandard or adulterated.
  • Delayed Approvals: Non-compliance issues can delay the approval of new drug applications or the review of existing product registrations.
  • Supply Chain Disruptions: Regulatory actions against a key API supplier can lead to severe shortages of essential medicines.

What are the critical intermediates and their suppliers for Ezetimibe and Simvastatin?

The synthesis of Ezetimibe and Simvastatin involves several complex chemical steps, requiring specialized intermediates. The availability and quality of these intermediates are crucial for the uninterrupted production of the final APIs.

• Ezetimibe Key Intermediates and Suppliers:

  • Key Intermediates:

    • (S)-4-Phenyl-2-oxazolidinone: A chiral intermediate essential for the stereoselective synthesis of Ezetimibe.
    • 4-(4-Fluorophenyl)-2-oxoazetidine-1-yl acetate: A key building block.
    • Various proprietary protected amino alcohols and phenolic compounds.

  • Supplier Landscape for Intermediates:

    • Aarti Industries (India): A significant producer of various pharmaceutical intermediates, including those for Ezetimibe.
    • Sudarshan Chemical Industries (India): Known for its expertise in organic synthesis and production of advanced intermediates.
    • Various Specialty Chemical Companies in India and China: A fragmented market with numerous smaller to medium-sized enterprises specializing in custom synthesis of intermediates. These companies often supply directly to API manufacturers or to larger intermediate consolidators.
    • Contract Development and Manufacturing Organizations (CDMOs): Many CDMOs offer custom synthesis services for Ezetimibe intermediates, providing flexibility and specialized capabilities.

• Simvastatin Key Intermediates and Suppliers:

  • Key Intermediates:

    • Lovastatin Acid: A precursor molecule.
    • (R)-2-Methylbutyric Acid derivatives: Used in the side chain synthesis.
    • Various lactone and ester intermediates.
    • Chiral building blocks for the side chain.

  • Supplier Landscape for Intermediates:

    • Divi's Laboratories (India): Besides producing Simvastatin API, Divi's also manufactures critical intermediates for the molecule.
    • Jubilant Life Sciences (India): A diversified company with strong capabilities in chemical synthesis and intermediate production.
    • BASF (Germany): A global chemical company that produces a range of specialty chemicals and intermediates, some of which are used in statin synthesis.
    • Chinese Chemical Manufacturers: A large number of Chinese companies supply a wide array of Simvastatin intermediates, often characterized by competitive pricing and large-scale production capabilities.

• Supply Chain Considerations for Intermediates:

  • Backward Integration: Some major API manufacturers have undertaken backward integration to secure the supply of critical intermediates, reducing reliance on external suppliers and controlling costs and quality.
  • Quality Control: The purity and quality of intermediates directly impact the yield and purity of the final API. Robust analytical testing and supplier qualification programs are essential.
  • Geopolitical Risks: Concentration of intermediate production in specific regions can expose supply chains to geopolitical tensions, trade disputes, or localized environmental regulations that could disrupt production.
  • Intellectual Property: While APIs and finished drugs are heavily patented, the synthesis routes and intermediates can also be subject to process patents, requiring careful navigation.

What are the market trends and future outlook for Ezetimibe and Simvastatin suppliers?

The market for Ezetimibe and Simvastatin APIs is characterized by mature product lifecycles, with demand driven by the prevalence of cardiovascular diseases and the continued use of these medications, particularly in generic formulations.

• Market Dynamics:

  • Generic Competition: Both Ezetimibe and Simvastatin are widely available as generics. This leads to intense price competition among API suppliers. Profit margins for APIs are often thin, necessitating efficient manufacturing processes and economies of scale.
  • Demand Stability: Despite the availability of newer lipid-lowering agents, Ezetimibe and Simvastatin remain foundational treatments due to their established efficacy, safety profiles, and affordability. Global demand is relatively stable, with growth primarily linked to population increases and healthcare access in emerging markets.
  • Regulatory Scrutiny: Increased regulatory oversight globally, particularly concerning impurities (e.g., nitrosamines), continues to shape the market. API manufacturers must invest in advanced analytical capabilities and process controls to meet these evolving standards.
  • Consolidation: The generic API sector is prone to consolidation as companies seek to achieve greater scale, reduce costs, and enhance their market position. This can lead to fewer, but larger, players dominating the supply landscape.

• Future Outlook for Suppliers:

  • Focus on Cost Efficiency and Process Optimization: Suppliers who can achieve the lowest cost of production through optimized manufacturing processes, efficient supply chain management, and high yields will remain competitive.
  • Robust Quality Management Systems: Suppliers with strong, well-documented quality management systems and a proven track record of regulatory compliance will be preferred by pharmaceutical companies, especially given the increasing scrutiny on product quality.
  • Supply Chain Resilience: Companies are increasingly prioritizing supply chain resilience. Suppliers located in diverse geographic regions or those with diversified manufacturing footprints may have an advantage. Suppliers who can offer transparency and reliability will be highly valued.
  • Investment in Technology: Adoption of advanced manufacturing technologies, such as continuous manufacturing or automation, could offer competitive advantages in terms of efficiency, quality, and cost.
  • Sustainability: Growing emphasis on environmental, social, and governance (ESG) factors may influence sourcing decisions. Suppliers demonstrating commitment to sustainable practices may gain a competitive edge.
  • Emerging Markets: Growth in healthcare expenditure and access to medicines in emerging economies will continue to drive demand for affordable generic APIs like Ezetimibe and Simvastatin.

• Potential Challenges:

  • Impurities Scrutiny: Ongoing regulatory focus on nitrosamine and other genotoxic impurities requires continuous vigilance and investment in analytical testing and process modification.
  • Geopolitical and Trade Risks: Trade tensions, tariffs, and geopolitical instability can impact raw material sourcing and finished API distribution.
  • Raw Material Price Volatility: Fluctuations in the cost of key starting materials and solvents can affect the profitability of API manufacturers.
  • Environmental Regulations: Increasingly stringent environmental regulations in key manufacturing regions can lead to higher operating costs and potential production limitations.

Key Takeaways

• The Ezetimibe and Simvastatin API markets are primarily supplied by manufacturers in India and China, with India holding a dominant share.
• Major suppliers for Ezetimibe include Zydus Lifesciences, Divi's Laboratories, and Laurus Labs.
• Key Simvastatin API providers are Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Aarti Industries.
• Regulatory compliance with US FDA, EMA, and other international standards is non-negotiable, with DMF filings, GMP certifications, and successful inspections being critical.
• The supply chains for these APIs rely on a network of intermediate manufacturers, with Aarti Industries and Sudarshan Chemical Industries significant for Ezetimibe, and Divi's Laboratories and Jubilant Life Sciences for Simvastatin.
• The market is characterized by mature generic products, intense price competition, and a growing emphasis on supply chain resilience, quality control, and regulatory adherence.

FAQs

1. Are there any significant regulatory changes anticipated that could impact Ezetimibe or Simvastatin API suppliers? Regulatory focus on nitrosamine impurities, genotoxic impurities, and enhanced supply chain transparency is expected to continue. Suppliers must maintain robust quality systems and analytical capabilities to adapt.

2. What is the typical lead time for sourcing Ezetimibe or Simvastatin API from major Indian or Chinese manufacturers? Lead times can vary significantly but typically range from 8 to 16 weeks for bulk API orders, depending on the supplier's existing production schedule, order volume, and raw material availability.

3. How do API manufacturers address potential supply chain disruptions for critical intermediates? Strategies include backward integration into key intermediate production, qualifying multiple suppliers for critical intermediates, and maintaining strategic buffer stocks.

4. What are the primary quality concerns associated with Ezetimibe and Simvastatin API procurement? Key concerns include API purity, absence of specified and unspecified impurities (including potential genotoxic impurities), residual solvents, and consistent batch-to-batch quality.

5. Can Ezetimibe and Simvastatin APIs be sourced from manufacturers in North America or Europe, and what are the implications? While limited, sourcing from North American or European manufacturers may offer benefits in terms of supply chain proximity and potentially reduced geopolitical risk, but often comes with higher cost structures compared to Asian suppliers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs — Major Changes to Approved Drug Products. Retrieved from https://www.fda.gov/ (Note: Specific guidance document title may vary, general FDA website used as a reference point for regulatory information.)

[2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/

[3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability. Retrieved from https://www.edqm.eu/

[4] Divi's Laboratories Limited. (Annual Reports). (Accessed for manufacturing capabilities and regulatory compliance statements).

[5] Laurus Labs Limited. (Annual Reports). (Accessed for manufacturing capabilities and regulatory compliance statements).

[6] Zydus Lifesciences Limited. (Annual Reports). (Accessed for manufacturing capabilities and regulatory compliance statements).

[7] Aarti Industries Limited. (Annual Reports). (Accessed for manufacturing capabilities and regulatory compliance statements).

[8] Dr. Reddy's Laboratories Limited. (Annual Reports). (Accessed for manufacturing capabilities and regulatory compliance statements).

[9] Sun Pharmaceutical Industries Limited. (Annual Reports). (Accessed for manufacturing capabilities and regulatory compliance statements).

[10] Pharmaceutical Technology. (Various articles and market reports on API manufacturing and supply chains).

[11] Various company press releases and investor presentations related to API manufacturing and expansion. (Accessed from company investor relations websites).